Evolv Technologies Holdings, INC. (EVLVW) — SEC Filings

Overview

Evolv Technologies Holdings, INC. (EVLVW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 13, 2025: Evolv Technologies Holdings, Inc. (EVLVW) reported a significant increase in total revenue to $42.85 million for the three months ended September 30, 2025, up 56.6% from $27.36 million in the prior-year period. This was driven by product revenue surging to $9.24 million from $1.34 million, and subsc

Sentiment Summary

Across 37 filings, the sentiment breakdown is: 1 bullish, 4 bearish, 31 neutral, 1 mixed. The dominant filing sentiment for Evolv Technologies Holdings, INC. is neutral.

Filing Type Overview

Evolv Technologies Holdings, INC. (EVLVW) has filed 5 10-Q, 18 8-K, 2 DEF 14A, 2 10-K, 6 SC 13G/A, 3 SC 13G, 1 SC 13D/A with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (37)

• Evolv Narrows Quarterly Loss on Strong Revenue Growth — 10-Q · Nov 13, 2025 Risk: medium
  Evolv Technologies Holdings, Inc. (EVLVW) reported a significant increase in total revenue to $42.85 million for the three months ended September 30, 2025, up 5
• Evolv Tech Swings to $40.5M Loss Amid Valuation Adjustments, Revenue Up — 10-Q · Aug 14, 2025 Risk: high
  Evolv Technologies Holdings, Inc. (EVLVW) reported a significant net loss of $40.5 million for the three months ended June 30, 2025, a substantial increase from
• Evolv Technologies Holdings Files Material Definitive Agreement — 8-K · Jul 30, 2025 Risk: medium
  On July 29, 2025, Evolv Technologies Holdings, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes financial statements
• Evolv Technologies Files 8-K — 8-K · Jul 1, 2025 Risk: low
  On July 1, 2025, Evolv Technologies Holdings, Inc. filed an 8-K report. The filing indicates a Regulation FD Disclosure, with no specific material events detail
• Evolv Technologies Holdings Reports on Shareholder Votes — 8-K · Jun 23, 2025 Risk: low
  Evolv Technologies Holdings, Inc. filed an 8-K on June 23, 2025, reporting on matters submitted to a vote of security holders as of June 20, 2025. The filing de
• Evolv Technologies Files Q1 2025 10-Q — 10-Q · May 20, 2025 Risk: low
  Evolv Technologies Holdings, Inc. filed its quarterly report for the period ending March 31, 2025. The company reported revenue from product sales, subscription
• Evolv Technologies Holdings Inc. DEF 14A Filing — DEF 14A · Apr 30, 2025 Risk: medium
  Evolv Technologies Holdings, Inc. filed a DEF 14A on April 30, 2025, detailing executive compensation and corporate governance matters for the fiscal year endin
• Evolv Technologies Files 2024 10-K — 10-K · Apr 28, 2025 Risk: medium
  Evolv Technologies Holdings, Inc. filed its 2024 10-K on April 28, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly NewHold In
• Evolv Technologies Holdings, Inc. Files 8-K — 8-K · Apr 23, 2025 Risk: medium
  Evolv Technologies Holdings, Inc. filed an 8-K on April 23, 2025, reporting events as of April 21, 2025. The filing includes information regarding the departure
• Evolv Technologies Faces Delisting Concerns — 8-K · Apr 22, 2025 Risk: high
  Evolv Technologies Holdings, Inc. filed an 8-K on April 22, 2025, reporting a notice of delisting or failure to satisfy continued listing rules. The filing indi
• Evolv Technologies Holdings, Inc. Reports Officer and Director Changes — 8-K · Feb 4, 2025 Risk: medium
  Evolv Technologies Holdings, Inc. filed an 8-K on February 4, 2025, reporting events as of January 31, 2025. The filing indicates changes related to the departu
• Evolv Tech Appoints New CMO, Director; Updates Comp. — 8-K · Jan 24, 2025 Risk: medium
  Evolv Technologies Holdings, Inc. announced on January 21, 2025, the appointment of Dr. Robert J. Smith as Chief Medical Officer and the election of Ms. Sarah C
• Evolv Technologies Holdings Reports 8-K Filing — 8-K · Jan 23, 2025 Risk: medium
  Evolv Technologies Holdings, Inc. filed an 8-K on January 23, 2025, reporting on events as of January 21, 2025. The filing covers results of operations, financi
• Evolv Technologies Adds Directors, Details Executive Pay — 8-K · Dec 23, 2024 Risk: low
  Evolv Technologies Holdings, Inc. announced on December 20, 2024, the election of two new directors, Dr. Robert J. Smith and Ms. Sarah E. Smith, to its Board of
• Evolv Technologies Announces Executive and Director Changes — 8-K · Dec 12, 2024 Risk: medium
  Evolv Technologies Holdings, Inc. announced on December 10, 2024, changes in its executive and director roles. The company appointed Dr. Robert J. Smith as Chie
• SC 13G/A Filing — SC 13G/A · Dec 12, 2024
• Evolv Technologies Holdings, Inc. Reports Officer and Director Changes — 8-K · Dec 9, 2024 Risk: medium
  Evolv Technologies Holdings, Inc. filed an 8-K on December 9, 2024, reporting events as of December 6, 2024. The filing indicates changes related to the departu
• Evolv Technologies Faces Nasdaq Delisting Warning — 8-K · Nov 22, 2024 Risk: high
  Evolv Technologies Holdings, Inc. announced on November 21, 2024, that it received a notice from the Nasdaq Stock Market indicating non-compliance with listing
• Evolv Technologies Appoints New Chief Medical Officer — 8-K · Nov 21, 2024 Risk: low
  Evolv Technologies Holdings, Inc. announced on November 20, 2024, the appointment of Dr. Michael J. Mulroy as Chief Medical Officer. Dr. Mulroy previously serve
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• SC 13G Filing — SC 13G · Nov 8, 2024
• SC 13G/A Filing — SC 13G/A · Nov 7, 2024
• SC 13G/A Filing — SC 13G/A · Nov 4, 2024
• Evolv Technologies Announces Board and CFO Changes — 8-K · Oct 31, 2024 Risk: medium
  Evolv Technologies Holdings, Inc. announced on October 30, 2024, changes in its board of directors and executive compensation arrangements. Specifically, the co
• Evolv Technologies to Restate Financials Due to Internal Control Weaknesses — 8-K · Oct 25, 2024 Risk: medium
  Evolv Technologies Holdings, Inc. announced on October 24, 2024, that it will restate its previously issued financial statements for the fiscal year ended Decem
• SC 13G Filing — SC 13G · Oct 24, 2024
• Evolv Technologies Holdings, Inc. Files Q2 2024 10-Q — 10-Q · Aug 8, 2024 Risk: medium
  Evolv Technologies Holdings, Inc. filed its quarterly report for the period ending June 30, 2024. The company, formerly known as NewHold Investment Corp., repor
• Evolv Technologies Holdings Files 8-K on Shareholder Votes — 8-K · Jun 4, 2024 Risk: low
  Evolv Technologies Holdings, Inc. filed an 8-K on June 4, 2024, reporting on matters submitted to a vote of security holders as of May 31, 2024. The filing deta
• Evolv Technologies Holdings, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk: medium
  Evolv Technologies Holdings, Inc. (EVLVW) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Evolv Technologies Holdings, Inc. filed a 10-Q report for
• SC 13G/A Filing — SC 13G/A · May 8, 2024
• Evolv Technologies Holdings, Inc. Files Definitive Proxy Statement (DEF 14A) — DEF 14A · Apr 15, 2024 Risk: low
  Evolv Technologies Holdings, Inc. (EVLVW) filed a Proxy Statement (DEF 14A) with the SEC on April 15, 2024. Evolv Technologies Holdings, Inc. filed a DEF 14A fo
• Evolv Technologies Holdings, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 29, 2024 Risk: medium
  Evolv Technologies Holdings, Inc. (EVLVW) filed a Annual Report (10-K) with the SEC on February 29, 2024. Evolv Technologies Holdings, Inc. filed its 2023 Form
• Evolv Technologies Files 8-K on Feb 19 Event — 8-K · Feb 20, 2024 Risk: medium
  Evolv Technologies Holdings, Inc. filed an 8-K on February 20, 2024, reporting an event that occurred on February 19, 2024. The filing indicates a current repor
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• Lux Venture Partners Amends Evolv Technologies Stake Disclosure — SC 13D/A · Feb 14, 2024 Risk: low
  Lux Venture Partners III, LLC filed an Amendment No. 2 to its Schedule 13D on February 14, 2024, regarding its beneficial ownership of Class A Common Stock of E
• BlackRock Discloses Passive Stake in Evolv Technologies — SC 13G · Feb 2, 2024
  BlackRock Inc., a major investment firm, filed an SC 13G on February 2, 2024, disclosing its ownership of Class A Common Stock in Evolv Technologies Holdings, I
• Evolv Technologies Confirms Nasdaq Listing for Stock & Warrants — 8-K · Jan 31, 2024
  Evolv Technologies Holdings, Inc. (EVLV) filed an 8-K on January 31, 2024, reporting that on January 29, 2024, their Class A common stock and warrants to purcha

Risk Profile

Risk Assessment: Of EVLVW's 27 recent filings, 3 were flagged as high-risk, 16 as medium-risk, and 8 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Evolv Technologies Holdings, INC.'s most recent 10-Q filing (Nov 13, 2025):

• Revenue: $42.85M
• Net Income: -$1.80M
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: $56.2M
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: $28.5M

Key Executives

• John Kedzierski
• Michael Ellenbogen
• Peter George
• Dr. Robert J. Smith
• Ms. Sarah Chen
• Ms. Sarah E. Smith
• Dr. Michael J. Mulroy
• Michael A. Smith
• David R. S. MacLeod
• Mark R. Johnson
• Peter Hebert
• Robert G. Minion, Esq.

Industry Context

Evolv Technologies operates in the rapidly evolving security technology sector, which is increasingly integrating AI and advanced analytics. The market is characterized by a growing demand for sophisticated threat detection and response solutions, driven by rising security concerns across various industries. Competition is intense, with both established security firms and innovative startups vying for market share.

Top Tags

corporate-governance (5) · disclosure (3) · 10-Q (3) · financials (3) · executive-compensation (3) · Evolv Technologies (3) · Security Technology (2) · AI-Powered Screening (2) · Revenue Growth (2) · Net Loss (2)

Key Numbers

• Total Revenue (Q3 2025): $42.85M — Increased 56.6% from $27.36 million in Q3 2024
• Product Revenue (Q3 2025): $9.24M — Increased from $1.34 million in Q3 2024
• Subscription Revenue (Q3 2025): $22.68M — Increased from $17.91 million in Q3 2024
• Net Loss (Q3 2025): $1.80M — Improved from a net loss of $30.44 million in Q3 2024
• Net Loss (YTD Sep 2025): $44.02M — Widened from $38.30 million in YTD Sep 2024
• Total Operating Expenses (Q3 2025): $29.90M — Decreased from $34.96 million in Q3 2024
• New Credit Facility: $75.0M — Secured with MidCap Financial Trust on July 29, 2025
• Long-term Debt (Sep 30, 2025): $28.5M — Drawn from the new credit facility
• Cash, Cash Equivalents, and Marketable Securities (Sep 30, 2025): $56.2M — Company's total liquidity
• Class A Common Stock Outstanding: 174,617,589 — As of November 7, 2025
• Net Loss: $40.5M — for the three months ended June 30, 2025, compared to $3.4M net income in Q2 2024
• Total Revenue: $32.5M — for the three months ended June 30, 2025, up from $25.2M in Q2 2024
• Subscription Revenue: $20.2M — for the three months ended June 30, 2025, a 28.9% increase from $15.6M in Q2 2024
• Total Other Expense, Net: $23.0M — for the three months ended June 30, 2025, primarily due to fair value changes in liabilities
• Cash and Cash Equivalents: $36.9M — as of June 30, 2025

Related Companies

EVLV

Frequently Asked Questions